Home » ACTELION SLUMPS ON CLAZOSENTAN STUDY OUTCOME
ACTELION SLUMPS ON CLAZOSENTAN STUDY OUTCOME
Swiss pharmaceutical company Actelion Ltd Monday said a study of its brain artery drug clazosentan showed that more time is needed to determine whether the product is effective, in a major setback that sent the shares sharply lower.
Therapeutics Daily
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May